Candidate tuning
Moieties and linkers can be explored to alter physicochemical and PK properties.
Industry partners
Pharmaceutical Platform
Explore the developmental PMF Prodrug Framework, target-delivery hypotheses, candidate tuning and confidential co-development pathway.
Why it matters
Pharmaceutical Platform
Explore the developmental PMF Prodrug Framework, target-delivery hypotheses, candidate tuning and confidential co-development pathway.
No ChronoSense pharmaceutical candidate is presented as approved. Candidate-specific CMC, pharmacology, safety, regulatory and clinical programs are required.
- Scientific rationale is distinguished from demonstrated outcomes.
- Capabilities are mapped to application, format and regulatory context.
- Confidential depth is available through qualified access rather than exposed publicly.
Designed as a platform
What makes this approach different
ChronoSense® connects the biological hypothesis to delivery, evidence, data and a controlled route to market.
Selective activation
Circadian-, tissue- or microenvironment-associated release hypotheses.
Target delivery
Local concentration and exposure strategies for defined biological objectives.
Extended half-life
Candidate-specific approaches to metabolism and clearance.
Development-stage assets
Structured scientific and technical diligence under confidential access.
Co-development
Shared program design, milestones, responsibilities and decision governance.
A disciplined pathway
From insight to accountable action
The platform is designed to move through explicit stages, with evidence and access appropriate to each one.
1
Define fit
Clarify market, application, route, territory and commercial objective.
2
Review evidence and feasibility
Use staged access to examine scientific, technical and supply readiness.
3
Agree the development plan
Set responsibilities, milestones, costs, claims and go/no-go decisions.
4
Execute and learn
Transfer, launch and improve under quality and brand governance.
Next step
Evaluate the pharmaceutical opportunity.
Qualified pharmaceutical and biotechnology teams can request a scientific and business-development discussion.